(Q42989774)

12 November 2017

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. (English)

1 reference

12 November 2017

1 reference

M Martinot-Peignoux

1

1 reference

12 November 2017

N Boyer

2

1 reference

12 November 2017

M Pouteau

3

1 reference

12 November 2017

C Castelnau

4

1 reference

12 November 2017

N Giuily

5

1 reference

12 November 2017

V Duchatelle

6

1 reference

12 November 2017

A Aupérin

7

1 reference

12 November 2017

C Degott

8

1 reference

12 November 2017

J P Benhamou

9

1 reference

12 November 2017

S Erlinger

10

1 reference

12 November 2017

P Marcellin

11

1 reference

12 November 2017

1 August 1998

1 reference

12 November 2017

Journal of Hepatology

1 reference

12 November 2017

29

1 reference

12 November 2017

214-223

1 reference

12 November 2017

2

1 reference

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Factors predictive of the response to interferon in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Factors affecting treatment responses to interferon-alpha in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

HCV viraemia is more important than genotype as a predictor of response to interferon in sicily (Southern Italy)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Implications of variations of "conserved" regions of hepatitis C virus genome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

A proposed system for the nomenclature of hepatitis C viral genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980006-8

7 January 2021

10.1016/S0168-8278(98)80006-8

Identifiers

DOI

1 reference

12 November 2017

1 reference